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Background
HLA-B*57 is the class I allele most consistently associated
with control of HIV replication, which may be linked to
the specific HIV peptides that this allele presents to cyto-
toxic T lymphocytes (CTL), and the resulting efficacy of
these cellular immune responses. In two clade-C HIV-
infected populations, we sought to elucidate the role of
HLA-B*5703 in HIV disease outcome.
Methods
We sequenced HIV-1 Gag p24 (from plasma RNA and
proviral DNA) from 645 South African and 178 Zambian
HIV-infected individuals, analyzed cross-sectional and
longitudinal viral load data, and performed viral replica-
tion assays on variants containing HLA-B*5703 escape
mutations.
Results
HLA-B*5703-restricted CTL responses select for escape
mutations in three Gag p24 epitopes, in a predictable
order, and we show here that the accumulation of these
mutations sequentially reduces viral replicative capacity in
vitro. Despite this, in vivo data demonstrate that ultimately
there is an increase in viral load concomitant with evasion
of all three HLA-B*5703-restricted CTL responses. In
HLA-B*5703-mismatched recipients, the previously
described early benefit of transmitted HLA-B*5703-asso-
ciated escape mutations is abrogated by the increase in
viral load coincident with reversion.
Conclusion
These data demonstrate that, while costly escape from
CTL responses can progressively attenuate the virus, high
viral loads develop in the absence of adequate, continued
CTL responses. These data underline the need for a CTL
vaccine against multiple conserved epitopes.
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